However, FG‐4592 inhibits the growth of melanoma and lung carcinoma tumors in murine models, in part by normalizing tumor blood vessels,(51) and increases vascularity in subcutaneous models of angiogenesis,(31) partially via in vivo induction of VEGF.(31, 33) The recent approval of FG‐4592 for clinical use(15, 16) highlights the need to accelerate research into this potential new strategy to treat osteolytic disease. Here, VEGFA is linked to lung carcinoma.